AdAlta Raises AU$1.2 Million to Advance PD1-Armoured CAR-T Cancer Therapy
Source: Kapitales Research
Highlights:
AdAlta has secured firm commitments to raise AU$1.2 million through a strategic placement to sophisticated investors.
Funds will support development of BZDS1901, a first-in-class PD1-armoured MSLN CAR-T therapy for advanced mesothelioma.
The placement follows strong investor interest after AdAlta’s recent licensing agreement with Shanghai Cell Therapy Group.
The capital raised enhances the company’s ability to implement its "East to West" cellular immunotherapy strategy.
Strategic Placement Completed
AdAlta Limited (ASX: 1AD) has completed an overnight strategic placement, raising AU$1.2 million before costs from a select group of high-net-worth and sophisticated investors. The placement was priced at AU$0.005 per share, with 240 million new fully paid ordinary shares issued.
For every two shares purchased in the placement, investors will receive one free attaching option, which can be exercised at AU$0.01, expiring on 3 June 2028. The placement was managed by 62 Capital Pty Ltd, which served as the lead manager.
Funding to Accelerate CAR-T Development
Proceeds from the placement will be used to advance development of BZDS1901, AdAlta’s next-generation CAR-T therapy targeting advanced mesothelioma. The funding also enhances balance sheet flexibility as the company progresses additional financing and partnering initiatives through its “East to West” strategy.
The capital raise follows AdAlta’s recent licensing of BZDS1901 from Shanghai Cell Therapy Group, which has significantly increased investor interest. Management noted that the placement was completed at a premium to the company’s October 2025 capital raise, reflecting improved market confidence following the licensing transaction.
Positioning for Next Phase
AdAlta said the funds may also be used to increase its interest in AdCella, its operating subsidiary, support regulatory engagement with the US Food and Drug Administration, and progress other pipeline opportunities. The placement strengthens the company’s negotiating position as it continues discussions around third-party funding and future collaborations.
Settlement of the placement shares is expected on 26 January 2026, with allotment and trading of the new shares and options anticipated shortly thereafter.
With funding secured, AdAlta is positioned to accelerate execution of its cellular immunotherapy programs and progress BZDS1901 toward the next stage of development.
Disclaimer for Kapitales Research
The materials provided by Kapitales Research, including articles, news, data, reports, opinions, images, charts, and videos ("Content"), are intended for personal, non-commercial use only. The primary goal of this Content is to educate and inform readers. This Content is not meant to offer financial advice, nor does it include any recommendation or opinion that should be relied upon for making financial decisions. Certain Content on this platform may be sponsored or unsponsored, but it does not serve as a solicitation or endorsement to buy, sell, or hold any securities, nor does it encourage any specific investment activities. Kapitales Research is not authorized to provide investment advice, and we strongly advise users to seek guidance from a qualified financial professional, such as a financial advisor or stockbroker, before making any investment choices. Kapitales Research disclaims all liability for any direct, indirect, incidental, or consequential damages arising from the use of the Content, which is provided without any warranties. The opinions expressed by contributors or guests are their own and do not necessarily reflect the views of Kapitales Research. Media such as images or music used on this platform are either owned by Kapitales Research, sourced through paid subscriptions, or believed to be in the public domain. We have made reasonable efforts to credit sources where appropriate. Kapitales Research does not claim ownership of any third-party media unless explicitly stated otherwise.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au
x
Daily Dose of Buy, Sell & Hold recommendations before the market opens.
Start Your 7 Days Free Trial Now!
We use cookies to help us improve, promote, and protect our services.
By continuing to use this site, we assume you consent to this.
Read our
Privacy Policy
and
Terms & Conditions
AdAlta Raises AU$1.2 Million to Advance PD1-Armoured CAR-T Cancer Therapy
Highlights:
Strategic Placement Completed
AdAlta Limited (ASX: 1AD) has completed an overnight strategic placement, raising AU$1.2 million before costs from a select group of high-net-worth and sophisticated investors. The placement was priced at AU$0.005 per share, with 240 million new fully paid ordinary shares issued.
For every two shares purchased in the placement, investors will receive one free attaching option, which can be exercised at AU$0.01, expiring on 3 June 2028. The placement was managed by 62 Capital Pty Ltd, which served as the lead manager.
Funding to Accelerate CAR-T Development
Proceeds from the placement will be used to advance development of BZDS1901, AdAlta’s next-generation CAR-T therapy targeting advanced mesothelioma. The funding also enhances balance sheet flexibility as the company progresses additional financing and partnering initiatives through its “East to West” strategy.
The capital raise follows AdAlta’s recent licensing of BZDS1901 from Shanghai Cell Therapy Group, which has significantly increased investor interest. Management noted that the placement was completed at a premium to the company’s October 2025 capital raise, reflecting improved market confidence following the licensing transaction.
Positioning for Next Phase
AdAlta said the funds may also be used to increase its interest in AdCella, its operating subsidiary, support regulatory engagement with the US Food and Drug Administration, and progress other pipeline opportunities. The placement strengthens the company’s negotiating position as it continues discussions around third-party funding and future collaborations.
Settlement of the placement shares is expected on 26 January 2026, with allotment and trading of the new shares and options anticipated shortly thereafter.
With funding secured, AdAlta is positioned to accelerate execution of its cellular immunotherapy programs and progress BZDS1901 toward the next stage of development.
Disclaimer for Kapitales Research
The materials provided by Kapitales Research, including articles, news, data, reports, opinions, images, charts, and videos ("Content"), are intended for personal, non-commercial use only. The primary goal of this Content is to educate and inform readers. This Content is not meant to offer financial advice, nor does it include any recommendation or opinion that should be relied upon for making financial decisions. Certain Content on this platform may be sponsored or unsponsored, but it does not serve as a solicitation or endorsement to buy, sell, or hold any securities, nor does it encourage any specific investment activities. Kapitales Research is not authorized to provide investment advice, and we strongly advise users to seek guidance from a qualified financial professional, such as a financial advisor or stockbroker, before making any investment choices. Kapitales Research disclaims all liability for any direct, indirect, incidental, or consequential damages arising from the use of the Content, which is provided without any warranties. The opinions expressed by contributors or guests are their own and do not necessarily reflect the views of Kapitales Research. Media such as images or music used on this platform are either owned by Kapitales Research, sourced through paid subscriptions, or believed to be in the public domain. We have made reasonable efforts to credit sources where appropriate. Kapitales Research does not claim ownership of any third-party media unless explicitly stated otherwise.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au